Theranica, an Israel-based biomedical technology company focused on developing advanced electroceuticals for migraine and other prevalent diseases, announced that Omron Ventures has joined its $35M series B funding round, which was announced earlier this March. The investment sum by Omron Ventures has not been disclosed.
Omron Ventures, the venture capital arm of Japan-based Omron Corporation and its affiliated companies, was established in July 2014 to target startups in Japan and the US. Last April, Ms Tomoko Inoue was appointed as the new CEO of Omron Ventures, after her predecessor Mr Naoshi Ozawa stepped down.
What’s the trend
In 2017, Omron Healthcare (US) and Samsung Next invested $1.5M in New York City-based Cohero Health, which develops connected health tools and technologies for chronic respiratory diseases, as part of its series A fundraising, which raised a total of $10.5M.
On the record
"Omron is a pioneer in innovative home medical equipment and therapeutic devices, and the recognition and commitment expressed by the decision of Ms Inoue and her team to make this strategic investment is highly valued and appreciated by Theranica,” said Alon Ironi, CEO and co-founder of Theranica in statement.
"Being the world’s leading manufacturer and distributor of personal health and wellness products, we are excited to partner with a company that shares Omron Healthcare’s mission of improving people’s health at home through science and technology,” said Tomoko Inoue, CEO of Omron Ventures.
“Theranica’s forward-thinking approach of investing in science, building strong physician-community relationships and developing health products that center around the patients and their ability to improve their own well-being is the right model for today and the future.”